Neurol. praxi. 2020;21(4):289-290 | DOI: 10.36290/neu.2020.085

Interferons-β treatment during pregnancy and breast-feeding

MUDr. Eva Meluzínová, MUDr. Jana Libertínová
Neurologická klinika 2. LF UK a FN Motol, Praha

Multiple sclerosis is autoimmune and neurodegenerative disease of central nervous system. The onset is usually between 20th and 30th year of life and females are affected three times more often than males. Thus, a large proportion of patients consists of women with childbearing potential and the choice of the treatment should reflect potential pregnancy planning very early in the course of the disease. In 2019 interferons-β have been assigned as the first line treatment options along with glatiramer acetate. The advantage of the treatment is a favourable safety profile not only in pregnancy but during lactation as well. Pregnancy planning, lactation and treatment strategies are discussed in this work.

Keywords: multiple sclerosis, interferon-β, glatiramer acetate, pregnancy, lactation.

Received: July 30, 2020; Revised: July 30, 2020; Accepted: July 30, 2020; Prepublished online: July 30, 2020; Published: September 8, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Meluzínová E, Libertínová J. Interferons-β treatment during pregnancy and breast-feeding. Neurol. praxi. 2020;21(4):289-290. doi: 10.36290/neu.2020.085.
Download citation

References

  1. Hanulíková P, Vlk R, Meluzínová E, Rob L. Těhotné s roztroušenou sklerózou ve FN Motol Praha 2003-2011: analýza dat Actual Gyn 2013; 5: 27-32 Manuscript ID: 0513008.
  2. Hellwig K, Caron F-D, Wicklein E-M, Bhatti A, Adamo A. Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure Ther Adv Neurol Disord. 2020; 13: 1756286420910310. Published online 2020 Mar 9doi: 10.1177/1756286420910310.PMCID: PMC7066586. Go to original source... Go to PubMed...
  3. Hellwig K, Geissbuehler Y, Sabidó M. Data from the European Interferon Beta Pregnancy Registry and Population Based Registries in Finland and Sweden. Presented at: 34th Congress of the European Committee for Treatment & Research in Multiple Sclerosis (ECTRIMS). October 10-12, 2018 | Berlin, Germany. P1753. Go to original source...
  4. Hellwig K, Rockhoff M, Herbstritt S, Borisow N, Haghikia A, Elias-Hamp B, Menck S, Gold R, Langer-Gould A. Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. JAMA Neurol 2015; 72(10): 1132-1138. Go to original source... Go to PubMed...
  5. Hener K (ed). Speciální neurologie, 1961.
  6. Kubala Havrdová E, Piťha J. Klinický doporučený postup pro diagnostiku a léčbu roztroušené sklerózy a neuromyelitis optica a onemocnění jejího širšího spektra, verze 2.0/2020.
  7. Lyons K-E, Ryan A, Dempsey E, Ross P, Stanton C. Breast Milk, a Source of Beneficial Microbes and Associated Benefits for Infant Health Nutrients 2020; 12(4): 1039. Go to original source... Go to PubMed...
  8. Maglione A, Rolla S, Mercanti SF, Cutrupi S, Clerico M. The Adaptive Immune. System in Multiple Sclerosis: An Estrogen-Mediated Point of View. Cells 2019; 8(10): pii: E1280. doi: 10.3390/cells8101280. Review. PubMed PMID: 31635066; PubMed Central PMCID: PMC6829884. Go to original source... Go to PubMed...
  9. Meluzínová E. Těhotenství a roztroušená skleróza. Neurol. praxi 2010; 11(5): 297-299.
  10. Paavilainen T, Kurki T, Parkkola R, Färkkilä M, Salonen O, Dastidar P, Elovaara I, Airas L. Eur Magnetic resonance imaging of the brain used to detect early post-partum activation of multiple sclerosis. J Neurol 2007; 14(11): 1216-1221. doi: 10.1111/j.1468-1331.2007.01927.x. Epub 2007 Aug 28.PMID: 17727663 Clinical Trial. Go to original source... Go to PubMed...
  11. Švihovec J (ed). Farmakologie, 2018.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.